JMJohn E. Moran

John E. Moran

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


John E. Moran has a total of 3 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Locking Solutions for Hemodialysis Catheters; Heparin and Citrate—A Position Paper by ASDIN

    by John E. Moran, Stephen R. Ash, the Clinical Practice Committee

    There is wide variation in the use of solutions to “lock” or fill tunneled central venous catheters for dialysis. Some centers use undiluted heparin concentrations ranging from 1000 to 10,000 U/ml and other centers place from 1000 to 10,000 U per lumen. Based on available evidence, it appears that heparin 1000 U/ml, or 4% sodium citrate are suitable choices for lock solution to maintain patency of tunneled central venous catheters for dialysis. Risks from systemic anticoagulation are lower with heparin 1000 U/ml and 4% sodium citrate, compared with higher concentrations of heparin (5000 and 10,000 U/ml). The need for use of tissue plasminogen activator for maintaining catheter patency is increased by using heparin lock at 1000 U/ml, vs. higher concentrations. Higher concentrations of heparin lock should be reserved for patients who have evidence of catheter occlusion or thrombosis when heparin is used at 1000 U/ml. Similar choices for lock solution are sensible for acute hemodialysis catheters. When heparin is used for catheter lock, the injected volume should not exceed the internal volume of the catheter.


  • Totally Implantable Subcutaneous Devices for Hemodialysis Access

    by J.E. Moran, F. Prosl

    Subcutaneous hemodialysis access systems represent a uniquely different hemodialysis access option. The ideal role for these devices is to help patients to achieve a functioning AV fistula by providing temporary access while patients are waiting for the creation or maturation of an AV fistula. An ideal bridge device would allow for immediate use following placement, provide blood flow rates sufficient to ensure adequate dialysis, have a low complication rate, and have sufficient length of technical survival to allow AV fistula development and maturation without the need for device replacement. Clinical data reported to date supports the use of subcutaneous hemodialysis access systems as a bridge device instead of a hemodialysis catheter [11, 12, 17-20]. The increased emphasis on AV fistula placements in patient populations who are at higher risk of having fistulas that fail to mature increases the need for a bridge device which provides improved outcomes during longer maturation periods especially in patients in whom more than one fistula attempt is made or for patients who are receiving upper arm fistulas [21, 36]. Several studies have also documented the utility of subcutaneous hemodialysis access systems in catheter-dependent patients who have exhausted other access options [12-15, 19, 20]. The hope offered for improved outcomes in this patient population should be tempered by realistic expectations for device performance especially in patients with significant morbidities, poor vasculature, a history of poorly performing hemodialysis catheters, or multiple catheter-related infections. Totally subcutaneous hemodialysis access systems offer a unique option for ESRD patients. The development of these devices represent a key step towards improving dialysis delivery and hemodialysis vascular access-related outcomes. Following recommended procedures for implanting, accessing and maintaining these devices is key towards achieving optimal device performance.